Our vision is to bring personalized gene therapy to the world. We target the root cause of genetic disease by introducing a functional copy of the affected gene into patients’ own hematopoietic stem cells (HSCs), with the goal of durably expressing the therapeutic protein throughout the body, including the central nervous system. Our first-in-class pipeline includes clinical programs for Gaucher disease and Hunter syndrome, as well as a preclinical program for Pompe disease. Our proprietary plato® gene therapy platform is scalable for planned global commercialization. We are headquartered in Cambridge, Mass. For additional information, visit avrobio.com, and follow us on Twitter and LinkedIn.
View Top Employees from AVROBIOWebsite | http://www.avrobio.com |
Ticker | AVRO |
Revenue | $23 million |
Funding | $284.7 million |
Employees | 87 (87 on RocketReach) |
Founded | 2015 |
Address | 100 Technology Sq 6th Floor, Cambridge, Massachusetts 02139, US |
Phone | (781) 962-6030 |
Technologies |
JavaScript,
HTML,
PHP
+37 more
(view full list)
|
Industry | Biotechnology Research, Business Services General, Biotechnology, Gene Therapy, Business Services, Science and Engineering, Cell Therapy, Genetics, Immune-Oncology, Health Care, Rare Disease |
Web Rank | 3 Million |
Keywords | Avrobio, Lab Ops Preclinical, Robio Ex, Hiv Patients Occupation In Usa, 2. Avrobio |
Competitors | AGTC, Adverum Biotechnologies, Freeline, MeiraGTx, Voyager Therapeutics, Inc. |
SIC | SIC Code 87 Companies, SIC Code 873 Companies |
NAICS | NAICS Code 541713 Companies, NAICS Code 541 Companies, NAICS Code 54 Companies, NAICS Code 5417 Companies, NAICS Code 54171 Companies |
Looking for a particular AVROBIO employee's phone or email?
The AVROBIO annual revenue was $23 million in 2024.
Azadeh Golipour is the CTO of AVROBIO.
87 people are employed at AVROBIO.
AVROBIO is based in Cambridge, Massachusetts.
The NAICS codes for AVROBIO are [541713, 541, 54, 5417, 54171].
The SIC codes for AVROBIO are [87, 873].